Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $1.5 billion, up 29.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 29.68% YoY), and the FY2025 annual result was $1.6 billion, up 27.53% from the prior year.
• Total Non-Current Liabilities slipped to $1.5 billion in Q1 2026 per RARE's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $1.6 billion in Q4 2025 and troughed at $301.3 million in Q2 2023.
• A 5-year average of $852.6 million and a median of $1.1 billion in 2025 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 288.61% in 2024 and fell as far as 72.43% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $317.5 million in 2022, then grew by 11.26% to $353.3 million in 2023, then jumped by 246.47% to $1.2 billion in 2024, then gained by 27.53% to $1.6 billion in 2025, then dropped by 5.0% to $1.5 billion in 2026.
• Business Quant data shows RARE's Total Non-Current Liabilities at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $410.6 million in Q3 2025.